



BioLineRx's Dr. Geffen will present results from Phase 2b EAGLE trial at Schizophrenia International Research Society (SIRS) Conference , Florence, Italy

April 13, 2010

On Thursday April 15, Yona Geffen, PhD, from BioLineRX will be presenting "A double-blind placebo control study evaluating the efficacy and safety of BL-1020 , a GABA enhanced antipsychotic for the treatment of schizophrenia" at the SIRS Conference, "Cognition in Schizophrenia" Session.